IDEXX Laboratories, Inc. (IDXX)
Valuation Overview•Is IDEXX Laboratories, Inc. Overvalued or Undervalued?
Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
High-quality fundamentals with a strong composite quality score of 87/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: High-quality compounder, with solvency as the only relative weakness.
Wall Street is highly bullish, projecting significant upside with steady expected earnings growth. This is paired with healthy capital returns, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
IDXX exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 42.5% ROIC). This is supported by a highly conservative balance sheet featuring strong liquidity and pristine Altman Z safety.
The company demonstrates solid revenue growth (8.5% 3Y CAGR) paired with robust earnings compounding (17.7% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 31.6% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | +10.4% | +8.5% | +9.7% | +10.4% | |
| EBITDA | $362.6M | — | +13.2% | — | — | |
| Net Income | $278.4M | +19.3% | +16.0% | — | +18.6% | |
| EPS (Diluted) | $3.45 | +22.6% | +17.7% | +14.3% | +20.4% | |
| Free Cash Flow | $0.00 | +32.0% | +38.8% | +14.3% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 62.1% | 60.9% | 60.2% | 58.2% |
| Operating Margin | 31.6% | 30.2% | 29.2% | 25.8% |
| Net Margin | 24.6% | 23.5% | 22.8% | 19.6% |
| FCF Margin | 19.0% | 22.0% | 19.5% | 17.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $3.41 | $3.47 | +1.8% | ||
| Q1'26 | $2.93 | $3.08 | +5.1% | ||
| Q4'25 | $3.14 | $3.40 | +8.3% | ||
| Q3'25 | $3.28 | $3.63 | +10.7% | ||
| Q2'25 | $2.85 | $2.96 | +3.9% | ||
| Q1'25 | $2.39 | $2.62 | +9.6% | ||
| Q4'24 | $2.68 | $2.80 | +4.5% | ||
| Q3'24 | $2.88 | $3.02 | +4.9% |
Total return is +8.1% (1Y), lagging the benchmark by -16.9%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -16.1% | -25.4% | — |
| 1Y | +8.1% | -16.9% | — |
| 3YCAGR | +5.2% | -15.3% | — |
| 5YCAGR | -1.3% | -14.5% | — |
| 10YCAGR | +20.2% | +6.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about IDEXX Laboratories, Inc. (IDXX) valuation, health, and returns.
IDEXX Laboratories, Inc. is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. overvalued (implying -53.0% downside from DCF intrinsic value of $264.13)
IDEXX Laboratories, Inc. has multiple valuation anchors: DCF Intrinsic Value: $264.13 | Peer Relative Fair Value: $241.10 | Wall Street Analyst Target: $747.50 (implying +33.0% upside). A convergence of these signals offers higher conviction.
IDEXX Laboratories, Inc. displays excellent financial health with a composite quality score of 87/100, supported by a Altman Z-Score of 20.5 (safe zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 42.5%.
IDEXX Laboratories, Inc. returns capital via buybacks instead of dividends, carrying a 2.7% buyback yield and reducing outstanding shares by -3.1% in the last 12 months.
IDEXX Laboratories, Inc.'s current growth trajectory is Stable. The company achieved +10.4% 1Y revenue growth and +22.6% 1Y EPS growth, compared to its 3Y revenue CAGR of +8.5%.
Wall Street consensus is Buy based on 22 analysts, beating EPS expectations in 100% of recent quarters with a 15-quarter streak. The consensus price target represents a +33.0% change from current levels.
Investment risks for IDEXX Laboratories, Inc. include: -31.0% 1-year max drawdown. Volatility risk is characterized by a beta of 1.30x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.